Trial intelligence / Profile preview

SCALOP-2: capecitabine chemoradiotherapy with or without nelfinavir and with standard- or high-dose radiotherapy for locally advanced pancreatic cancer

2013-004968-56Phase 2Unknown

Sponsor
University of Oxford
Start
Oct 2015
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, randomised, open-label trial of nelfinavir and capecitabine in pancreatic cancer (PC) (4 arms), sponsored by University of Oxford. Primary endpoints: Maximum tolerated dose of nelfinavir and Safety. Status: unknown.

02

Drugs

nelfinavircapecitabine
03

Conditions

pancreatic cancer (PC)

Beyond the preview

Go deeper on 2013-004968-56.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2013-004968-56.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call